Abstract:AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 3857 To investigate the role of mutant p 5 3 in lung tumorigenesis, a p53(273H) transgenic mouse model was developed. The transgene was placed under control of the human surfactant protein C (SPC) promoter to selectively express the mutant protein in lung tissue. In the previous report we summarized the lung tumor incidence of the transgenic mice up to age cohort of 13-15 months. The p53 (273H) transgenic mice were found to have a higher lung tumor rate compared to the non-transgenic controls at median age of 14 months. We continued our study and collected the lung cancer incidence data up to 24 months. A total of 236 transgenic mice and 189 non-transgenic control mice were evaluated by necropsy at age of 4-6, 7-9, 10-12, 13-15, 16-18, 19-21, and 22-24 months. Among the 236 transgenic mice, 58 lung tumor bearing mice were identified. Among the 189 non-transgenic mice, 22 lung tumor bearing mice were identified. All tumors were identified histopathologically as adenocarcinomas. By comparison, no difference was found in lung tumor rate between the transgenic mice and non-transgenic controls at age of 4-12 and 22-24 months. However, the transgenic mice have a statistically (two tailed t-test) significant higher lung tumor rate than their non-transgenic counterparts during the age of 13-21 months. These results indicate that expression of mutant p53 in mice lungs cause early onset of lung tumor in the transgenic mice. The long latency period for tumors to develop would suggest that in the event that the mutant p53(273H) contributes to the development of lung tumors in these mice, other genetic alterations or age related physiological changes occurring after age of 13 moth are required for malignant transformation. At the age of 22-24 months, many other genetic alterations have occurred so that mutant p53 is no longer a major event in lung tumorigenesis.

p53 mutant mice that display early ageing-associated phenotypes

Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity.

Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging

Expression of a Mutant P53 in Lung Specific Transgenic Mice Cause Age-Related Demographic Shift in Lung Tumor Incidence

Gene expression profiling of aging reveals activation of a p53-mediated transcriptional program

Mouse models to investigate in situ cell fate decisions induced by p53

High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

Functional Diversity of P53 in Human and Wild Animals

REGγ Deficiency Promotes Premature Aging Via the Casein Kinase 1 Pathway.

p53 regulates diverse tissue-specific outcomes to endogenous DNA damage in mice

Generation and Characterization of P53 Mutant Mice.

Mice Deficient In Rbm38, A Target Of The P53 Family, Are Susceptible To Accelerated Aging And Spontaneous Tumors

Senescence Aging, And Malignant Transformation Mediated By P53 In Mice Lacking The Brcal Full-Length Isoform

Chromosome Stability, in the Absence of Apoptosis, is Critical for Suppression of Tumorigenesis in Trp53 Mutant Mice

Puma is Required for P53-Induced Depletion of Adult Stem Cells

Senescence regulation by the p53 protein family.

Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.

Effects of genetic background on tumorigenesis in p53-deficient mice

Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6-deficient mice.

p21 deletion rescues stem cell senescence and premature ageing of telomere dysfunctional mice without accelerating cancer formation

Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome